CTRI/2024/04/066217
Recruiting
Phase 3
Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NI
Amrita School of Pharmacy0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecified
- Sponsor
- Amrita School of Pharmacy
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(a) patients who are on the Memantine arm of CTRI/2022/01/039599 Trial
- •(b) Patients who are willing to participate in the study, and provide informed consent
Exclusion Criteria
- •(a) Patients who are on the placebo Arm of CTRI/2022/01/039599 Trial
- •(b) Patients who are not willing to participate in the study, and provide informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Influence of therapeutic drug monitoring (TDM) on the tolerability and efficacy of 5-FU-containing chemotherapy in patients with colorectal carcinoma in the colorectal center at St.-Franziskus-Hospital Münster: a prospective, monocentric observational study.C18Malignant neoplasm of colonDRKS00026926St. Franziskus-Hospital GmbH50
Withdrawn
Not Applicable
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000447954Royal Brisbane & Women's Hospital150
Recruiting
Not Applicable
TDM in MMTOpiod dependenceMental Health - AddictionACTRN12606000033549The Langton Centre90
Active, not recruiting
Phase 1
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208
Active, not recruiting
Not Applicable
Effectiveness of theraPeutic drug mOnitoring (TDM) on mucosal and transmural healing in pediatric patients with moderate to severe luminal CroHn’s disease newly receiving Remsima(infliximab): EPOCH studyDiseases of the digestive systemKCT0005190Samsung Medical Center116